March 27, 2015: Genfit announced yesterday that after massaging the data in a recent clinical trial, it hopes to continue with a late-stage trial later this year. Genfit stock took a beating on the news.
March 27, 2015: Novo Nordisk will resubmit its NDA of its insulin treatment Tresiba and related drug Ryzodeg to the U.S. FDA after interim analysis of the drug’s cardiovascular effects.
March 27, 2015: Ohr released results from its Phase II IMPACT study today, which evaluated OHR-102 for the treatment of the wet form of age-related macular degeneration. The treatment failed to achieve its primary endpoint, and shares of the company are now down more than 60 percent.
March 27, 2015: This month marks the 30th anniversary of BioSpace—and that means we here in the newsroom are taking a look back at all the major milestones for biotech in the last three decades, as the sector, and its innovations, have boomed. By March 2015, BioSpace has published more than 600,000 news stories from...